ARCHIVES

FDA To Once Again Review ESA Label To Reflect Results Of Negative Studies.

This article is from The Cancer Letter archive.

Vol. 33 No. 45 | December 7, 2007

Download PDF Visit The Full Archive

Related Articles

Panel Urges Research On DCIS To Identify Women At High Risk For Invasive Cancer

September 25, 2009

MEPACT Approved In Europe For Resectable Osteosarcoma

March 27, 2009

NIH Defines Misconduct

December 9, 1994

In Brief: David Kessler Nominated For FDA; Salahuddin Sentenced to Research; B.J. Kennedy Honored

October 26, 1990

Duke Comprehensive Cancer Center Wins Core Grant Renewal

September 17, 2010

PFS Is A Benefit “In The Right Context,” Pazdur Says In Q&A On Avastin Approval.

February 29, 2008